Name

Core Scientific Creations

Legal name

Core Scientific Creations Ltd.

Website

https://woundclot.org

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Hemostatic Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA), Wound Care, Bandaging & Consumables (Dressings, Sutures, Staplers) (HLAMAFAF), Tissue Engineering & Biomaterial Scaffolds (HLAMANAC)

Keywords

• Hemostatic gauze products
• Advanced bleeding control
• Cellulose hemostatic devices
• Surgical hemostatic devices
• Trauma wound care

Headquarters

HQ city

Kfar Saba

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Hemostatic Medical Devices: Core Scientific Creations generates revenue through the sale of WoundClot hemostatic gauze products. These are medical devices sold to healthcare providers, emergency responders, and military organizations for bleeding control applications. The company sells directly through quote-based procurement for institutional customers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Core Scientific Creations develops and manufactures the WoundClot™ family of hemostatic gauze products made from cellulose using a patented Non-Oxidized, Non-Regenerated Cellulosic Structure (NONRCS) process. These FDA-cleared and CE Class III certified implantable medical devices are used for rapid bleeding control in surgical, trauma, hemodialysis post-procedure, and veterinary applications. The product converts from a dry flexible gauze to a thick, tenacious 3D gel matrix upon contact with blood, absorbing up to 2,500-3,000% of its weight while activating clotting factors to achieve hemostasis.

Product overview

Core Scientific Creations develops the WoundClot™ family of hemostatic gauze products, which are FDA-cleared medical devices made from cellulose using a patented Non-Oxidized, Non-Regenerated Cellulosic Structure (NONRCS) process. The portfolio includes four product lines: WoundClot™ Surgical (a CE Class III implantable hemostatic for surgical procedures), WoundClot™ Trauma (for pre-hospital emergency responders managing traumatic wounds), WoundClot™ Twin Pack (designed specifically for post-hemodialysis bleeding control), and WoundClot™ Veterinarian (for veterinary applications). All products share the same core technology platform—a cellulose-based gauze that converts to a 3D gel matrix upon contact with blood, achieving hemostasis through absorption, adhesion, aggregation, and activation of clotting factors. The technology absorbs up to 2,500-3,000% of its weight in blood and remains actively absorbent for up to 24 hours.

Differentiator

Problem solved

Functional benefit

Brands

• WoundClot™ Surgical: Bioabsorbable CE Class III implantable hemostatic effective in management of capillary, venous, and arterial bleeding during surgical procedures
• WoundClot™ Trauma
• WoundClot™ Twin Pack
• WoundClot™ Veterinarian

Products and services

• WoundClot™ Surgical A bioabsorbable CE Class III Implantable hemostatic device effective in the management of capillary, venous, and arterial bleeding during surgical procedures. Uses Non-Oxidized, Non-Regenerated Cellulosic Structure (NONRCS) technology intended for trauma surgery, cardiovascular surgery, plastic surgery, orthopedic surgery, OB/GYN, EENT, interventional medicine, and other surgical applications.
• WoundClot™ Trauma A next-generation hemostatic gauze intended for bleeding control of traumatic wounds, including moderate to severe bleeding. Designed for use by trained emergency responders, military personnel, law enforcement, and EMS in pre-hospital and tactical settings.
• WoundClot™ Twin Pack A twin-pack configuration featuring 2 pieces of WoundClot™ hemostatic gauze designed for post hemodialysis bleeding control at arteriovenous fistula access sites or for post-procedure bleeding in interventional medicine.
• WoundClot™ Veterinarian A next-generation hemostatic gauze indicated for the control of mild, moderate, and severe bleeding in veterinary applications. Available in sizes including 10cm x 10cm, 8cm x 20cm, and 8cm x 100cm for veterinary surgical procedures and animal trauma care.

Quantifiable outcome

• WoundClot use shortened bleeding time significantly - mean venous bleeding time decreased by 3.99 minutes and mean arterial bleeding time by 6.38 minutes compared to cotton gauze (p < 0.001) in hemodialysis AVF decannulation study
• +3 more outcomes

Segments6 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Ethicon (Johnson & Johnson): Ethicon, a J&J subsidiary, makes Surgicel (oxidized regenerated cellulose) and other surgical hemostats widely used in operating rooms. Surgicel is the established ORC hemostatic that WoundClot Surgical directly differentiates against with its NONRCS structure.
• Baxter International: Baxter manufactures Floseal, Tisseel, and other surgical hemostats/sealants used in operating rooms globally. A broad incumbent in the surgical hemostasis space that overlaps with WoundClot Surgical in clinical use cases, though Baxter's products are protein/sealant-based rather than gauze-based.
• Becton Dickinson (BD): BD produces a broad surgical and hemostasis portfolio through its BD Interventional and Medical Surgical segments, supplying hospitals and EMS with hemostatic devices, surgical supplies, and adjacent wound-care products. Overlaps with WoundClot in hospital and surgical procurement channels.
• Integra LifeSciences: Integra LifeSciences manufactures a broad portfolio of surgical and wound-care products including regenerative wound matrices (Integra Dermal Regeneration Template) that overlap with WoundClot in surgical hemostasis and advanced wound management, though via different technology platforms.

Direct peers

• BioCer Entwicklungs-GmbH: BioCer develops Chitogauze and other chitosan-based hemostatic products serving military, EMS, and surgical markets. Smaller specialty competitor with overlapping product mechanism and customer overlap to WoundClot.
• Z-Medica (Teleflex): Z-Medica, now part of Teleflex, manufactures QuikClot Combat Gauze, the standard-issue military hemostatic and the leading kaolin-based gauze competitor to WoundClot. It is the closest direct peer in product category, customer base (military, EMS, hospitals), and clinical positioning.
• Advanced Medical Solutions: Advanced Medical Solutions (AMS) is a UK-based wound care and surgical adhesives specialist that produces hemostatic products (e.g., ActivHeal, LiquiBand) competing with WoundClot in surgical and emergency wound management across European and global markets.
• Tricol Biomedical (HemCon): Tricol Biomedical produces HemCon chitosan-based hemostatic dressings and other chitosan wound-care products that compete with WoundClot in trauma and surgical hemostasis. Comparable in product mechanism and target customer (military, EMS, hospitals).
• Medtrade Products: Medtrade Products manufactures Celox, a chitosan-based hemostatic gauze directly competing with WoundClot in trauma, EMS, and military channels. Celox uses a single mechanism (chitosan), making it a direct functional comparator to WoundClot's multi-mechanism NONRCS gauze.

Emerging players

• Hemostasis Today: Hemostasis Today (or comparable specialty hemostatic start-ups such as Cresilon/Hemostatic Gel) are emerging competitors developing next-generation hemostatic technologies for trauma and surgical use. They represent the emerging-technology frontier that WoundClot competes against for the next wave of hospital and military procurement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Core Scientific Creations